Eli Lilly and Co

Change company Symbol lookup

Select an option...

LLY Eli Lilly and Co

TFPM Triple Flag Precious Metals Corp

SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027

GMBL Esports Entertainment Group Inc

CFRX ContraFect Corp

AAL American Airlines Group Inc

NVDA NVIDIA Corp

AMD Advanced Micro Devices Inc

QQQ Invesco QQQ Trust

AAPL Apple Inc

Go

$1.15M contribution from Lilly will fund the purchase and installation of 150 refrigeration units by Direct Relief in low- and middle-income countries around the world Eli Lilly and Company (NYSE: LLY) and Direct Relief today announced a new...(PR Newswire)

First of its kind collaboration creates a new pathway for career opportunities to communities historically underrepresented in professional jobs Be Nimble Foundation, a 501(c)(3) social enterprise creating fully diverse and inclusive tech...(PR Newswire)

Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least...(PR Newswire)

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial, which showed Jardiance(R) (empagliflozin) tablets significantly reduced the risk of kidney disease progression* or cardiovascular death in...(PR Newswire)

Accelerated approval application was based on Phase 2 trial showing amyloid plaque lowering Complete response letter based on limited number of patients with 12-month drug exposure data in the accelerated approval submission; no other deficiencies...(PR Newswire)

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial...(PR Newswire)

Eli Lilly and Company (NYSE: LLY) will attendthe 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat at 6:45 p.m. Eastern time. (PR Newswire)

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the...(PR Newswire)

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries (PR Newswire)

-- Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and pirtobrutinib; potential regulatory submissions for...(PR Newswire)

The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on outstanding common stock. (PR Newswire)

-- Jardiance(R) (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged 10-17 living with type 2 diabetes compared to...(PR Newswire)

The benefit of adjuvant Verzenio in combination with endocrine therapy continues to deepen with additional follow-up, now demonstrating an absolute improvement in invasive disease-free survival (IDFS) and distance relapse-free survival (DRFS) rates...(PR Newswire)

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition ofAkouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class...(PR Newswire)

Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm(R)(aducanumab-avwa)-treated patients at 6 months Donanemab reduced brain amyloid plaque levels vs. baseline by 65.2%...(PR Newswire)

FN Media Group Presents USA News Group News Commentary USA News Group- A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this...(PR Newswire)

Eli Lilly and Company(NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the...(PR Newswire)

Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial...(PR Newswire)